The peptide upregulates expression of epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor among others
Its mechanism places it in a different research category than direct-acting lipolytic peptides
Preclinical studies lasting up to 6 weeks showed no adverse effects across liver, spleen, lung, kidney, brain, thymus, prostate, and ovary tissues
No randomized controlled trial has been conducted, and none could ethically be conducted in which pregnant women are randomly assigned to take or withhold acetaminophen to study autism outcomes
What this means for researchers now The practical takeaway is this: semaglutide is the known quantity, retatrutide is the exciting frontier, and the field will continue evolving rapidly regardless of which compound someone chooses today